References of "Deutsche Medizinische Wochenschrift (1946)"
     in
Bookmark and Share    
Peer Reviewed
See detail[Cardiology in Great Britain].
Neyses, Ludwig UL

in Deutsche medizinische Wochenschrift (1946) (2006), 131(24), 1409-11

Detailed reference viewed: 57 (0 UL)
Peer Reviewed
See detail[Potassium restriction and essential hypertension].
Neyses, Ludwig UL

in Deutsche medizinische Wochenschrift (1946) (1992), 117(35), 1341

Detailed reference viewed: 79 (0 UL)
Peer Reviewed
See detailKalium-Restriktion und essentielle Hypertonie
Neyses, Ludwig UL

in Deutsche Medizinische Wochenschrift (1946) (1991), (116), 2417-2248

Detailed reference viewed: 104 (0 UL)
Peer Reviewed
See detail[Disturbed endothelium-dependent blood vessel relaxation in essential hypertension].
Neyses, Ludwig UL; Vetter, H.

in Deutsche medizinische Wochenschrift (1946) (1990), 115(51-52), 1981

Detailed reference viewed: 53 (0 UL)
Peer Reviewed
See detailHypertensive Herzkrankheit - pathophysiologische Grundlaten, Diagnostik und Therapie
Neyses, Ludwig UL; Vetter, H

in Deutsche Medizinische Wochenschrift (1946) (1990), (39), 1480-1486

Detailed reference viewed: 73 (0 UL)
Peer Reviewed
See detail[Hypertensive heart disease. Pathophysiological foundation, diagnosis and therapy].
Neyses, Ludwig UL; Vetter, H.

in Deutsche medizinische Wochenschrift (1946) (1990), 115(39), 1480-6

Detailed reference viewed: 54 (0 UL)
Peer Reviewed
See detail[Elevated plasma flecainide concentrations in heart failure].
Nitsch, J.; Neyses, Ludwig UL; Kohler, U. et al

in Deutsche medizinische Wochenschrift (1946) (1987), 112(44), 1698-700

In 42 patients with heart failure who were on long-term treatment with flecainide (2 X 100 mg daily by mouth) plasma concentration of flecainide was measured before the morning dose and compared with the ... [more ▼]

In 42 patients with heart failure who were on long-term treatment with flecainide (2 X 100 mg daily by mouth) plasma concentration of flecainide was measured before the morning dose and compared with the clinical grade of heart failure or left ventricular ejection fraction (in the levo-angiogram). Mean plasma flecainide concentration was 415 +/- 244 ng/ml (110-1035 ng/ml), mean ejection fraction 55 +/- 17.7% (24-84%) (r = -0.60). In seven patients with plasma concentrations over 700 ng/ml (870 +/- 150 ng/ml) in clinical grade III or IV, ejection fractions were 24, 25, 25, 30, 33, 37 and 44%, respectively. In two patients (ejection fraction of 24 and 25%, respectively) the morning plasma concentration was around 1000 ng/ml. The results point to possible high plasma flecainide concentrations--at times in the toxic range--in patients who are in heart failure. In patients with marked reduction in left ventricular pumping function who are on long-term flecainide treatment, a reduction in dosage or monitoring of plasma flecainide concentration is indicated. [less ▲]

Detailed reference viewed: 58 (0 UL)